Hemoglobin infusion augments the tumor necrosis factor response to bacterial endotoxin (lipopolysaccharide) in mice.
暂无分享,去创建一个
[1] D. Su,et al. Hemoglobin increases mortality from bacterial endotoxin , 1997, Infection and immunity.
[2] R. Rabinovici,et al. Liposome-encapsulated hemoglobin modulates lipopolysaccharide-induced tumor necrosis factor-alpha production in mice. , 1997, Critical care medicine.
[3] R. Roth. Hemoglobin Enhances the Binding of Bacterial Endotoxin to Human Endothelial Cells , 1996, Thrombosis and Haemostasis.
[4] S. Opal,et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.
[5] J. Langermans,et al. Safety evaluation of a polymerized hemoglobin solution in a murine infection model. , 1996, The Journal of laboratory and clinical medicine.
[6] M. Fink,et al. Effect of human hemoglobin on systemic and regional hemodynamics in a porcine model of endotoxemic shock. , 1996, Critical care medicine.
[7] C. Dinarello,et al. Biologic basis for interleukin-1 in disease. , 1996, Blood.
[8] J. Ogden,et al. Haemoglobin‐Based Red Cell Substitutes: Current Status , 1995, Vox sanguinis.
[9] A. Cross,et al. The importance of a lipopolysaccharide-initiated, cytokine-mediated host defense mechanism in mice against extraintestinally invasive Escherichia coli. , 1995, The Journal of clinical investigation.
[10] B. Schröppel,et al. PROTECTIVE EFFECTS OF HYDROXYETHYL STARCH‐DEFEROXAMINE IN EARLY SEPSIS , 1995, Shock.
[11] J. Jones. Red blood cell substitutes: current status. , 1995, British journal of anaesthesia.
[12] K. Burhop,et al. THE EFFECTS OF DIASPIRIN CROSS-LINKED HEMOGLOBIN IN SEPSIS , 1995 .
[13] Jan A. M. Langermans,et al. Haemoglobin-based blood substitutes and infection , 1995, The Lancet.
[14] D. Pepper,et al. Haemoglobin-based blood substitutes and sepsis , 1995, The Lancet.
[15] R. Roth,et al. Human hemoglobin increases the biological activity of bacterial lipopolysaccharides in activation of Limulus amebocyte lysate and stimulation of tissue factor production by endothelial cells in vitro , 1994 .
[16] R. Roth,et al. Hemoglobin, a newly recognized lipopolysaccharide (LPS)-binding protein that enhances LPS biological activity. , 1994, The Journal of biological chemistry.
[17] R. Roth. Hemoglobin enhances the production of tissue factor by endothelial cells in response to bacterial endotoxin. , 1994, Blood.
[18] E. Abraham. Clinical sepsis trials. , 1994, Chest.
[19] J. Bonaventura,et al. Cell-free hemoglobin reverses the endotoxin-mediated hyporesponsivity of rat aortic rings to alpha-adrenergic agents. , 1994, Biochemical and biophysical research communications.
[20] R. Roth,et al. Production of modified crosslinked cell‐free hemoglobin for human use: the role of quantitative determination of endotoxin contamination , 1993, Transfusion.
[21] R. Bone,et al. Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.
[22] J. Eaton,et al. Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[23] W. Fiers,et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia , 1993, The Journal of experimental medicine.
[24] K. Feingold,et al. Role for monokines in the metabolic effects of endotoxin. Interferon-gamma restores responsiveness of C3H/HeJ mice in vivo. , 1992, The Journal of clinical investigation.
[25] R. Bone,et al. Sepsis syndrome. New insights into its pathogenesis and treatment. , 1991, Infectious disease clinics of North America.
[26] P. Brandtzaeg,et al. Current understanding of the pathogenesis of gram-negative shock. , 1991, Infectious disease clinics of North America.
[27] J. Eaton,et al. Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[28] H. Büller,et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways , 1990 .
[29] Robert C. Thompson,et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.
[30] P. Brandtzaeg,et al. Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response , 1989, The Journal of experimental medicine.
[31] A. Cerami,et al. Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.
[32] T. Ikejima,et al. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. , 1988, The Journal of clinical investigation.
[33] D. Remick,et al. Acute in vivo effects of human recombinant tumor necrosis factor. , 1987, Laboratory investigation; a journal of technical methods and pathology.
[34] J. D. Albert,et al. Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.
[35] B. Beutler,et al. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.
[36] J. Berzofsky,et al. The murine Kupffer cell. I. Characterization of the cell serving accessory function in antigen-specific T cell proliferation. , 1979, Journal of immunology.
[37] I. Cohn,et al. Enhancement of Escherichia coli infection and endotoxic activity by hemoglobin and ferric ammonium citrate. , 1970, Surgery.
[38] H. Rogers,et al. The effect of iron compounds on the virulence of Escherichia coli for guinea-pigs. , 1968, Immunology.
[39] E. Hook,et al. THE INFLUENCE OF HEMOLYSIS OR BLOOD LOSS ON SUSCEPTIBILITY TO INFECTION. , 1963, Journal of immunology.
[40] C. W. Walter,et al. Synergistic Toxicity of Gram‐negative Bacteria and Free Colloidal Hemoglobin , 1963, Annals of surgery.
[41] K. Kaushansky,et al. A new year greeting from a new editor , 1998, Blood.
[42] N. Hsia,et al. The toxicities of native and modified hemoglobins. , 1997, Free radical biology & medicine.
[43] W. Alvord,et al. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. , 1995, The Journal of infectious diseases.
[44] R. Winslow,et al. Pilot-scale preparation of hemoglobin solutions. , 1994, Methods in enzymology.
[45] I. Cohn,et al. Hemoglobin as a bacterial virulence-enhancing factor in fluids produced in strangulation intestinal obstruction. , 1968, The American surgeon.